Robert W. Baird Lowers Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00
Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price objective decreased by Robert W. Baird from $12.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock. Other equities analysts also recently issued reports about the company. Canaccord Genuity Group reaffirmed a “buy” rating […]
Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price objective decreased by Robert W. Baird from $12.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock. Other equities analysts also recently issued reports about the company. Canaccord Genuity Group reaffirmed a “buy” rating […]
